Myasthenia gravis with anti-acetylcholine receptor antibodies

Frontiers of Neurology and Neuroscience

Volumn 26, Issue , 2009, Pages 94-108

  Meriggioli, Matthew N ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EDROPHONIUM CHLORIDE; EN 101; ENZYME ANTIBODY; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MESTINON TIMESPAN; MUSCLE ANTIBODY; MUSCLE SPECIFIC RECEPTOR TYROSINE KINASE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; PYRIDOSTIGMINE; RITUXIMAB; STRIATED MUSCLE ANTIBODY; TACROLIMUS; UNCLASSIFIED DRUG; AUTOANTIBODY; CHOLINERGIC RECEPTOR; DIAGNOSTIC AGENT;

B LYMPHOCYTE; CELLULAR IMMUNITY; DIPLOPIA; DISEASE CLASSIFICATION; DRUG DOSE TITRATION; DRUG MEGADOSE; ELECTROMYOGRAPHY; EYE DISEASE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INTUBATION; LOW DRUG DOSE; MUSCLE WEAKNESS; MYASTHENIA; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NEUROMUSCULAR TRANSMISSION; PATHOGENESIS; PATHOLOGY; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; PTOSIS; REGULATORY T LYMPHOCYTE; REVIEW; SENSITIVITY AND SPECIFICITY; THYMECTOMY; THYMOMA; THYMUS; THYMUS HYPERPLASIA; WEAKNESS; CLASSIFICATION; IMMUNOLOGY;

AUTOANTIBODIES; HUMANS; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC;

EID: 67649684333     PISSN: 16604431     EISSN: 16622804     Source Type: Book Series    
DOI: 10.1159/000212371     Document Type: Review

References (48)

1. Phillips LH 2nd: The epidemiology of myasthenia gravis. Ann NY Acad Sci 2003;998:407-12.
2. Grob D, Brunner N, Namba T, Pagala M: Lifetime course of myasthenia gravis. Muscle Nerve 2008;37: 141-149.
3. Vincent A: Unraveling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2002;2:797-804.
4. Jaretski A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB: Myasthenia gravis: recommendations for clinical research standards. Task force of the Medical and Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16-23.
5. Compston DAS, Vincent A, Newsom-Davis J, Batchelor JR: Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 1980;103:579-601.
6. Romi F, Skeie GO, Gilhis NE, Aarli JA: Striational antibodies in myasthenia gravis. Arch Neurol 2005; 62:442-426.
7. Romi F, Skeie GO, Aarli JA, Gilhus NE: The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Arch Neurol 2000;57:1596-1600.
8. Romi F, Gilhus NE, Varhaug JE, Myking A, Aarli JA: Disease severity and outcome in thymoma myasthenia: a long-term observational study. Eur J Neurol 2003;10:701-706.
9. Vernino S, Lennon VA: Autoantibody profiles and neurological correlations of thymoma. Clin Cancer Res 2004;10:7270-7275.
10. Kupersmith MJ, Latkany R, Homel P: Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 2003;60:243-248.
11. Pascuzzi RM: The edrophonium test. Semin Neurol 2003;23:83-88.
12. Meriggioli MN, Sanders DB: Advances in the diagnosis of neuromuscular disorders. Am J Phys Med Rehabil 2005;84:627-637.
13. Vincent A, Newsom-Davis J: Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2,967 diagnostic assays. J Neurol Neurosurg Psychiat r y 1985;48:1246-1252.
14. Lennon VA: Serological diagnosis of myasthenia gravis and Lambert-Eaton myasthenic syndrome; in Lisak RP (ed): Handbook of Myasthenia Gravis and Myasthenic Syndromes. New York, Dekker, 1994, pp 149-164.
15. McKeon A, Lennon VA, Jacob A, Matiello M, Lucchinetti CF, Kale N, Chan KH, Weinshenker BG, Apiwattinakui M, Wingerchuk DM, Pittock SJ: Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve 2009;39:87-90.
16. Howard FM Jr, Lennon VA, Finley J, Matsumoto J, Elveback LR: Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann NY Acad Sci 1987;505:526-538.
17. Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan PB, Beeson D, Willcox N, Vincent A: IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008;131:1940-1952.
18. Drachman DB, Adams RN, Stanley EF, Pestronk A: Mechanisms of acetylcholine receptor loss in myasthenia gravis. J Neurol Neurosurg Psychiatry 1980; 43:601-610.
19. Protti MP, Manfredi AA, Straub C, Howard JF Jr, Conti-Tronconi BM: Immunodominant regions for T helper-cell sensitization on the human nicotinic receptor alpha subunit in myasthenia gravis. Proc Natl Acad Sci USA 1990;87:7792-7796.
20. Willcox N, Leite MI, Kadota Y, Jones M, Meager A, Subrahmanyam P, Dasgupta B, Morgan B P, Vincent A: Autoimmunizing mechanisms in thymoma and thymus. Ann NY Acad Sci 2008;1132:163-173.
21. Schluep M, Willcox N, Vincent A, Dhoot GK, Newsom-Davis J: Acetylcholine receptors in human thymic myoid cells in situ: an immunohistochemical study. Ann Neurol 1987;22:212-222.
22. Morgenthaler TI, Brown LR, Colby T V, Harper CM Jr, Coles DT: Thymoma. Mayo Clin Proc 1993;68: 1110-1123.
23. Argov Z, McKee D, Agus S, Brawer S, Shlomowitz N, Yoseph OB, Soreq H, Sussman JD: Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase. Neurology 2007;69: 699-700.
24. Batocchi AP, Evoli A, Dischino C, Tonali P: Therapeutic apheresis in myasthenia gravis. Ther Apher 2000;4:275-279.
25. Psaridi-Linardaki L, Trakas N, Mamalaki A, Tzartos SJ: Specific immunoadsorption of the autoantibodies from myasthenia gravis patients using the extracellular domain of the human muscle acetylcholine receptor alpha-subunit. Development of an antigen specific therapeutic strategy. J Neuroimmunol 2005; 159:183-189.
26. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C: Clinical trial of plasma exchange and high dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 1997;41:789-796.
27. Zinman L, Ng E, Bril V: IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007;68:837-841.
28. Pascuzzi RM, Coslett HB, Johns TR: Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984;15:291-298.
29. Evoli A, Batocchi AP, Palmisani MT, Lo Monaco M, Tonali P: Long-term results of corticosteroid therapy in patients with myasthenia gravis. Eur Neurol 1992;32:37-43.
30. Witte AS: Azathioprine in the treatment of myasthenia gravis. Ann Neurol 1984;15:602-605.
31. Palace J, Newsom-Davis J, Lecky B: A randomized double-blind trial of prednisone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998;50:1778-1783.
32. Chaudhry V, Cornblath DR, Griffin J W, O-Brien R, Drachman DB: Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001;56:94-96.
33. Meriggioli MN, Ciafaloni E, Al-Hayk KA, Rowin J, Tucker-Lipscomb B, Massey JM, Sanders DB: Mycophenolate mofetil in the treatment of myasthenia gravis: an analysis of efficacy, safety and tolerability. Neurology 2003;61:1438-1440.
34. The Muscle Study Group: A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008;71:394-399.
35. Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqui ZA, DeBaets MH, Melms A, Nicolle M W, Solomons N, Richman DP: An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008;71:400-406.
36. Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K: A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann NY Acad Sci 1993;681:539-551.
37. Ciafaloni E, Nikhar NK, Massey JM, Sanders DB: Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology 2000;55:448-450.
38. De Feo LG, Schottlender J, Martelli NA, Molfino NA: Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve 2002;26:31-36.
39. Drachman DB, Jones RJ, Brodsky RA: Treatment of refractory myasthenia: 'rebooting' with high-dose cyclophosphamide. Ann Neurol 2003;53:29-34.
40. NaganeY, Utsugisawa K, Obara D, Knodoh R, Terayama Y: Efficacy of low-dose FK-506 in the treatment of myasthenia gravis-a randomized pilot study. Eur Neurol 2005;53:146-150.
41. Tandan R, Potter C, Bradshaw DY: Pilot trial of rituximab in myasthenia gravis. Neurology 2008; 70(Suppl 1):A301.
42. Gronseth GS, Barohn RJ: Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:7-15.
43. Thomas CE, Mayer SA, Gungor Y, Swarup R, Webster EA, Chang I, Brannagan TH, Fink ME, Rowland LP: Myasthenia crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 1997;48:1253-1260.
44. Seneviratne J, Mandrekar J, Wijdicks E F, Rabinstein AA: Noninvasive ventilation in myasthenic crisis. Arch Neurol 2008;65:54-58.
45. Zhou Y, Gong B, Lin F, Rother R P, Medof ME, Kaminski HJ: Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J Immunol 2007;179:8562-8567.
46. Rowin J, Meriggioli MN, Tüzün E, Leurgens S, Christadoss P: Etanercept treatment in steroid-dependent autoimmune myasthenia gravis. Neurology 2004;63:2390-2392.
47. Sheng JR, Li L, Ganesh BB, Prabhakar BS, Meriggioli MN: Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia. Clin Immunol 2008;128:172-180.
48. Meriggioli MN (ed): Myasthenic Disorders and ALS. Continuum Lifelong Learning Neurol 2009; 15(1).